Kaken Pharmaceutical: revenue up 24.4% as milestones and Aadi lift profit
Kaken Pharmaceutical's H1 net sales rose 24.4% to ¥48.96bn and operating profit reached ¥10.16bn, per TradingView. The FY2026 outlook holds.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Kaken Pharmaceutical's first-half net sales climbed 24.4% year on year to ¥48.96bn, while operating profit came in at ¥10.16bn.
Overseas revenue got a lift from the Aadi and Fyarro products and a milestone payment from J&J. TradingView, citing an AI-generated summary of the company's filing, says the 2026 fiscal guidance is still on track, with KP-001 and Ekterly leading pipeline progress.
why it matters
Profit growth relied on one-off milestone payments and contributions from partnered products, so investors will likely watch whether momentum carries into the second half. Confirmed guidance and progress on KP-001 and Ekterly matter for the company's outlook.
market impact
Kaken Pharmaceutical shares: strong half-year sales and profit support the stock
- Kaken Pharmaceutical shares pressure up — first-half sales and profit growth, partly from one-off milestone payments
tags
instruments
sources
- Kaken Pharmaceutical: Revenue rose 24.4%, while operating profit reached ¥10.2bn on milestone and Aadi contributions — TradingView, 9 November 2026 at 09:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗